Previous 10 | Next 10 |
Array BioPharma is up 56% after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is higher by 8.35% after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...
Voyager Therapeutics (NASDAQ: VYGR ) -3.4% pre-market on news it is restructuring its gene therapy relationship with Sanofi Genzyme (NASDAQ: SNY ). More news on: Voyager Therapeutics, Inc., Sanofi, Neurocrine Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Biotech targets that could see some interest today per Bloomberg after Pfizer ponied up a 62% premium for Array Bio Pharma include Biohaven (NYSE: BHVN ), Seattle Genetics (NASDAQ: SGEN ), Arena Pharmaceuticals (NASDAQ: ARNA ), Sage Therapeutics (NASDAQ: SAGE ), Sarepta Therapeutics (NASDAQ:...
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...
SAN DIEGO , June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatme...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 10:00 a.m. PT ( 1:00 p.m. ET ) on Tuesday, June 11, 2019 , in Rancho Palos Verdes, Calif. Kevin Gorman , Chief Exec...
SAN DIEGO , May 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday , June 6, 2019, in New York . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Finan...
AbbVie (NYSE: ABBV ) and licensor Neurocrine Biosciences (NASDAQ: NBIX ) announce the commercial availability of the 200 mg twice-daily regimen (for up to six months) of ORILISSA (elagolix) for the treatment of moderate to severe pain associated with endometriosis. More news on: AbbVie...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...